Horsham, PA (September 27, 2018) – Janssen Biotech, Inc. (Janssen) announced today its decision not to continue the collaboration and license agreement with Geron Corporation for imetelstat. The decision not to continue the collaboration is the result of a strategic portfolio evaluation and prioritization of assets within the robust Janssen portfolio. Janssen will work with Geron to transition the imetelstat program back to the company. Patients currently enrolled in the ongoing imetelstat clinical trials will continue to be supported through the respective trial protocols, including treatment and follow-up.
The imetelstat collaboration began on November 13, 2014 when Janssen entered into an exclusive worldwide collaboration and license agreement with Geron to develop and commercialize imetelstat in oncology, including hematologic myeloid malignancies.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal. Janssen Biotech, Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.